Ovarian Cancer


Focus on Front Line and establish an urgent need to treat patients as early as possible to delay recurrence.

Key Selling Message

Front-line Avastin significantly delays recurrence in patients with Stage IIIb–IV ovarian cancer

  • Convince clinicians that treating in FL as early as possible maximises PFI with 20% more patients progression free 6 months after completion of chemotherapy.
  • Continue to establish PFS benefit in FL patients when Avastin is continued beyond chemotherapy OS data in high risk Stage IV patients.